DVYSR — Devyser Diagnostics AB Income Statement
0.000.00%
- SEK1.62bn
- SEK1.53bn
- SEK216.90m
Annual income statement for Devyser Diagnostics AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 65.7 | 93.5 | 127 | 169 | 217 |
Cost of Revenue | |||||
Gross Profit | 47 | 71.9 | 103 | 145 | 173 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 76.6 | 115 | 179 | 228 | 275 |
Operating Profit | -10.9 | -21.2 | -52 | -58.9 | -58.3 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -11.9 | -21.9 | -52.7 | -54.4 | -57.6 |
Provision for Income Taxes | |||||
Net Income After Taxes | -10.9 | -20.7 | -46 | -53.6 | -61.5 |
Net Income Before Extraordinary Items | |||||
Net Income | -10.9 | -20.7 | -46 | -53.6 | -61.5 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -10.9 | -20.7 | -46 | -53.6 | -61.5 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.521 | -1.85 | -2.95 | -3.3 | -3.73 |
Dividends per Share |